Heinz Lubenau

Heinz Lubenau

Company: NEC OncoImmunity

Job title: Chief Drug Development Officer


Employing Oral Bacteria-Based DNA Vaccine Targeting Neoantigens 11:30 am

Identifying neoantigen-specific immune responses Highlighting the benefits of oral administration Implementing a comprehensive set of biomarkers in checkpoint inhibitor combination studies to assess the neoantigen-treatment-related effectRead more

day: Conference Day One

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.